D
iffuse midline gliomas with histone H3 lysine27-to-methionine mutations (H3K27M-glioma) are uniformly fatal malignancies (1) . They are both spatially and temporally restricted, occurring in midline structures of the brain with peak incidence at 6 to 9 years of age. These patterns suggest that a particular cell type, potentially undergoing rapid expansion at this stage, is susceptible to transformation by H3K27M. Experimental models suggest that neural precursor cells (NPCs) can be transformed in vitro by H3K27M, in combination with TP53 mutation and PDGFRA overexpression (2) . H3K27M suppresses EZH2, the catalytic subunit of Polycomb Repressive Complex 2 (PRC2), compromising epigenetic repression and potentially affecting cellular differentiation (1) (2) (3) . In patient samples, little is known about the developmental cell states present or how they cooperate with H3K27M for tumorigenesis. Single-cell RNA sequencing (scRNA-seq) can help address such questions by characterizing cancer cell states, their proliferative signatures, and their similarity to normal or other malignant cell types. scRNA-seq also helps relate single cell states to genetics through inferred chromosomal copy number variations (CNVs) or mutation detection in expressed transcripts (4) (5) (6) .
We obtained fresh tissue from diagnostic biopsies of six H3K27M-glioma (table S1 and fig. S1 ). Each sample was dissociated into single cells, flow sorted, and profiled by means of full-length scRNA-seq ( fig. S2) (7, 8) . We retained 2458 cells that passed quality controls (8) (table S2) . The cells' profiles group primarily by tumor of origin (Fig. 1A and fig. S3 ), but two clusters contain cells from multiple tumors, expressing markers of either microglia (such as CD14, CX3CR1, and AIF1) or oligodendrocytes (such as MBP and PLP1) (Fig. 1, A and B) , suggesting that they are nonmalignant cells. Accordingly, in presumed malignant cells only, we detected evidence for cancer-specific aberrations-point mutations and/or CNVs (4-6)-in 93.7% of cells in five of the six tumors (Fig. 1, C and D, and figs. S4 to S7). Thirty-four percent (833 of 2458) of the cells had H3K27M mutations in scRNA-seq reads mapping to H3F3A or HIST1H3B (Fig. 1D and  fig. S7 ) only detected in presumed malignant cells; other point mutations from whole-genome sequencing (WGS)/whole-exome sequencing (WES) (tables S1 and S2) were also detected only in presumed malignant cells (Fig. 1D and fig. S7 ) (8) . Analyzing a seventh tumor (MUV17) with H3F3A-specific primers in the scRNA-seq protocol confirmed H3K27M in 97% of the presumed malignant cells ( fig. S8) (8) .
Next, we compared malignant cell transcriptomes across different glioma types, including H3K27M-glioma, isocitrate dehydrogenase (IDH)-mutant oligodendroglioma (IDH-O), IDH-mutant astrocytoma (IDH-A), and IDH-wild-type glioblastoma (GBM) ( fig. S9A and tables S3 and S4) (5, 6, 9) . Many genes were up-regulated in H3K27M-glioma versus other tumors (n = 182 genes), but few were down-regulated (n = 12 genes), which is consistent with H3K27M blocking repression by PRC2 ( fig.  S9 , B to D). Accordingly, H3K27M-up-regulated genes are enriched for PRC2 target genes (P < 0.0001, hypergeometric test) ( fig. S9E) (10, 11) . The PRC1 subunit BMI1 was up-regulated in H3K27M-glioma, possibly representing a compensatory mechanism for PRC2 suppression. Suppression of BMI1 by means of CRISPR knockout or its pharmacological inhibition reduced viability of H3K27M glioma cells, relative to treatment controls and non-H3K27M glioma lines ( fig. S10) (12) .
We next assessed patterns of intratumor heterogeneity and distinguished subpopulations of malignant cells within H3K27M-glioma. We identified four programs (P1 to P4) that were consistently observed as variable within tumors and across computational methods (8) : cell cycle (such as PCNA and CDK1), astrocytic differentiation (AC-like) (such as GFAP and APOE), oligodendrocytic differentiation (OClike) (such as MBP and PLP1), and OPC-like programs (such as PDGFRA and CSPG4) (Fig.  2, A and B; figs. S11 and S12; and table S5) (13, 14) .
Scoring each cell for these expression programs highlighted a putative developmental hierarchy, in which proliferation is largely restricted to OPClike cells that presumably both self-renew and give rise to the OC-like and AC-like cells (Fig. 2C) . The relative fraction of cells in each compartment (OPC-like, AC-like, and OC-like) varied between tumors, but OPC-like cells were consistently the most prevalent ( fig. S13 ). We validated this cellular composition with RNA in situ hybridization (ISH) of seven tumor specimens (table S4) , using markers for OPC-like, AC-like, and cycling cells (PDGFRA, APOE, and Ki-67, respectively) ( Fig. 2D and fig. S13 ). Analysis of normal brain cell types indicated that PRC2 targets are highly expressed by OPCs and lowly expressed by OCs (P < 0.05, Student's t test) (fig. S14 and table S6). Thus, OPC differentiation into OC may require the repressive activity of PRC2 and may be hindered by PRC2 inactivation through H3K27M, which may result in accumulation of self-renewing OPC-like cells. Accordingly, some tumors had little evidence of lineage differentiation ( fig. S13 ). Furthermore, knockout of the OPC lineage factor PDGFRA by use of CRISPR/Cas9 reduced viability in two models of H3K27M-glioma ( fig. S15 ). Combined targeting of PDGFRA and the PRC1 subunit BMI1 further reduced viability of these models ( fig. S15 ). Thus, OPC-like cells are the predominant subpopulation of H3K27M tumors, propagate the disease in patients, and may be susceptible to therapeutic strategies that concurrently target lineage-defined (PDGFRA) and somatically altered (BMI1) cellular programs.
The H3K27M-glioma hierarchy resembles that in IDH-mutant gliomas; both contain a cycling stem-like subpopulation and differentiated subpopulations of OC-like and AC-like cells. However, they differ in the proportions of subpopulations and in the exact set of genes associated with each program (5, 6). We scored malignant cells from both cohorts by the signatures for H3K27M and IDH-mutant gliomas (5, 6). Astrocytic programs were highly similar (Fig. 3, A and B) , whereas oligodendrocytic and stem-like programs are largely distinct, with only a small set of shared genes (Fig. 3, C to F stem cell genes were expressed highly by OPCs (such as PDGFRA), whereas IDH-specific stem cell genes were expressed by NPCs (such as SOX11) (Fig. 3 , F and G) (5, 6) . Additionally, H3K27M-glioma harbored more cycling and undifferentiated cells than IDH-mutant gliomas (Fig. 3H) , potentially accounting for their more aggressive behavior. We next considered how this cellular architecture relates to genetic heterogeneity and tumor evolution. CNV analysis and inference of haplotypes uncovered distinct genetic subclones in two tumors (Fig. 3, I and J, and figs. S16 and S17) (8) . Although all cells in BCH869 have lost one copy of chromosome 14, the subclones had different haplotypes, indicating that two distinct events led to loss of alternate chromosome 14 alleles (Fig. 3J) . Additionally, certain somatic gene mutations could be assigned to just one of the subclones (Fig. 3K) . Use of both CNVs and haplotype frequencies enabled inference of phylogenetic trees (Fig. 3L, fig. S17D , and table S7) (8) . Each genetic subclone contained cells spanning a similar diversity of cellular states, although with some variation in their relative proportions (Fig.  3M and fig. S17E ). This suggests that distinct genetic subclones share similar developmental hierarchies in H3K27M-glioma. Next, we profiled 863 single cells from several models derived from BCH869-including patientderived xenograft (PDX), gliomaspheres (GS), and differentiated glioma cells (DGC) (fig. S18) (15) and compared them with cells from the corresponding tumor. Cells from the PDX most closely approximated malignant cell states in the primary tumor, whereas each in vitro model recapitulated some, but not all, of these states (Fig. 4, A and  B, and fig. S19A ). Tumor-initiation capacity was exclusive to cells grown in GS conditions (n = 8 of 8 mice) that partially recapitulated the OPC-like state, and was abolished in DGCs that mirrored the AC-like state (n = 0 of 8 mice) (Fig. 4C and fig. S19 , B and C), supporting the functional relevance of the inferred hierarchies. Last, we identified differentially expressed genes between the primary tumor, PDX, and culture models ( Fig. 4D and table S8) . A large number of genes were down-regulated in culture models compared with the primary tumor, including glioma-related oncogenes (such as epidermal growth factor receptor), putative stemness genes (such as SOX2, RFX4, and CD133), and PRC2-targets (P < 10
) (10). PRC2 targets were further down-regulated in DGC (compared with GS), along with neurodevelopmental regulators such as SOX6 and SOX10 (Fig. 4D) . This highlights the specificities and limitations of each model. scRNA-seq of primary H3K27M-glioma defines a putative developmental hierarchy and contrasts the underlying stem cell and differentiation programs with other classes of glioma. malignant cells; (iii) differentiation hierarchies play a critical role in the functional properties of glioma cells because self-renewal and tumorpropagating potential are exclusive to the most primitive cells; and (iv) genetic subclones in tumors tend to share similar cellular architecture. Our study also highlights opportunities for therapeutic intervention. We show that OPC-like cells drive H3K27M-glioma, suggesting that the OPC marker PDGFRA could be a lineage-defined therapeutic target, relevant even in the absence of genetic amplification or mutation. H3K27M-glioma also overexpress the PRC1 subunit BMI1 and are sensitive to its inhibition, either alone or in combination with PDGFRA inhibition, hinting at a potential compensatory mechanism for PRC2 dysfunction (Fig. 4E) . Thus, lineage-defined and somatically altered cellular programs in H3K27M-glioma suggest complementary opportunities for therapeutic intervention in these incurable malignancies.
